pbs_code
stringlengths 5
6
| drug
stringclasses 15
values | brand
stringclasses 29
values | formulation
stringclasses 35
values | indication
stringclasses 7
values | treatment_phase
stringclasses 53
values | streamlined_code
stringclasses 33
values | online_application
bool 2
classes | authority_method
stringclasses 2
values | hospital_type
stringclasses 3
values | schedule_code
int64 4.03k
4.03k
| schedule_year
int64 2.02k
2.02k
| schedule_month
stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
9458T | etanercept | Brenzys | Injection 50 mg in 1 mL single use auto-injector, 4 | psoriatic arthritis | Continuing treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
9458T | etanercept | Enbrel | Injection 50 mg in 1 mL single use auto-injector, 4 | psoriatic arthritis | Continuing treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
12577Y | infliximab | Remsima SC | Solution for injection 120 mg in 1 mL pre-filled pen | rheumatoid arthritis | Initial treatment with the subcutaneous form where a concurrent PBS authority application for the intravenously (IV) administered formulation is being made | null | true | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
10900Q | secukinumab | Cosentyx | Injection 150 mg in 1 mL pre-filled pen | psoriatic arthritis | Initial treatment - Initial 1 (new patient) | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
10900Q | secukinumab | Cosentyx | Injection 150 mg in 1 mL pre-filled pen | psoriatic arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in in biological medicine of less than 5 years) | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
10900Q | secukinumab | Cosentyx | Injection 150 mg in 1 mL pre-filled pen | psoriatic arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
9104E | adalimumab | Hyrimoz | Injection 40 mg in 0.8 mL pre-filled pen | ankylosing spondylitis | First continuing treatment | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
9104E | adalimumab | Hadlima | Injection 40 mg in 0.8 mL pre-filled pen | ankylosing spondylitis | First continuing treatment | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
9104E | adalimumab | Abrilada | Injection 40 mg in 0.8 mL pre-filled pen | ankylosing spondylitis | First continuing treatment | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
9104E | adalimumab | Idacio | Injection 40 mg in 0.8 mL pre-filled pen | ankylosing spondylitis | First continuing treatment | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
9104E | adalimumab | Amgevita | Injection 40 mg in 0.8 mL pre-filled pen | ankylosing spondylitis | First continuing treatment | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
9104E | adalimumab | Hyrimoz | Injection 40 mg in 0.8 mL pre-filled pen | ankylosing spondylitis | Subsequent continuing treatment | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
9104E | adalimumab | Hadlima | Injection 40 mg in 0.8 mL pre-filled pen | ankylosing spondylitis | Subsequent continuing treatment | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
9104E | adalimumab | Abrilada | Injection 40 mg in 0.8 mL pre-filled pen | ankylosing spondylitis | Subsequent continuing treatment | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
9104E | adalimumab | Idacio | Injection 40 mg in 0.8 mL pre-filled pen | ankylosing spondylitis | Subsequent continuing treatment | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
9104E | adalimumab | Amgevita | Injection 40 mg in 0.8 mL pre-filled pen | ankylosing spondylitis | Subsequent continuing treatment | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
9104E | adalimumab | Hyrimoz | Injection 40 mg in 0.8 mL pre-filled pen | ankylosing spondylitis | Continuing treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
9104E | adalimumab | Hadlima | Injection 40 mg in 0.8 mL pre-filled pen | ankylosing spondylitis | Continuing treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
9104E | adalimumab | Abrilada | Injection 40 mg in 0.8 mL pre-filled pen | ankylosing spondylitis | Continuing treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
9104E | adalimumab | Idacio | Injection 40 mg in 0.8 mL pre-filled pen | ankylosing spondylitis | Continuing treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
9104E | adalimumab | Amgevita | Injection 40 mg in 0.8 mL pre-filled pen | ankylosing spondylitis | Continuing treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
13293P | adalimumab | Humira | Injection 20 mg in 0.2 mL pre-filled syringe | juvenile idiopathic arthritis | Continuing treatment | 14136 | true | STREAMLINED | Public | 4,030 | 2,024 | AUGUST |
11521J | golimumab | Simponi | Injection 50 mg in 0.5 mL single use pre-filled pen | non-radiographic axial spondyloarthritis | Continuing treatment | null | true | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
11521J | golimumab | Simponi | Injection 50 mg in 0.5 mL single use pre-filled pen | non-radiographic axial spondyloarthritis | Continuing treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
1423X | tocilizumab | Actemra | Concentrate for injection 200 mg in 10 mL | juvenile idiopathic arthritis | Initial treatment - Initial 1 (new patient) | null | true | AUTHORITY_REQUIRED | Private | 4,030 | 2,024 | AUGUST |
1423X | tocilizumab | Actemra | Concentrate for injection 200 mg in 10 mL | juvenile idiopathic arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break of more than 12 months) | null | true | AUTHORITY_REQUIRED | Private | 4,030 | 2,024 | AUGUST |
1423X | tocilizumab | Actemra | Concentrate for injection 200 mg in 10 mL | juvenile idiopathic arthritis | Initial treatment - Initial 2 (retrial or recommencement of treatment after a break of less than 12 months) | null | true | AUTHORITY_REQUIRED | Private | 4,030 | 2,024 | AUGUST |
1423X | tocilizumab | Actemra | Concentrate for injection 200 mg in 10 mL | juvenile idiopathic arthritis | Balance of supply for Initial treatment - Initial 1 (new patient) or Initial 2 (retrial or recommencement of treatment after a break of less than 12 months) or Initial 3 (recommencement of treatment after a break of more than 12 months) | null | true | AUTHORITY_REQUIRED | Private | 4,030 | 2,024 | AUGUST |
11743C | tocilizumab | Actemra Subcutaneous Injection | Injection 162 mg in 0.9 mL single use pre-filled syringe | giant cell arteritis | Initial treatment | null | true | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
12084B | tocilizumab | Actemra ACTPen | Injection 162 mg in 0.9 mL single use pre-filled pen | juvenile idiopathic arthritis | Continuing treatment in a patient weighing at least 30 kg | 14088 | true | STREAMLINED | Any | 4,030 | 2,024 | AUGUST |
13345J | tofacitinib | Xeljanz | Tablet 5 mg | ankylosing spondylitis | Continuing treatment | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
13345J | tofacitinib | Xeljanz | Tablet 5 mg | ankylosing spondylitis | Continuing treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
13345J | tofacitinib | Xeljanz | Tablet 5 mg | ankylosing spondylitis | Transitioning from non-PBS to PBS-subsidised supply - Grandfather arrangements | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
12795K | tocilizumab | Actemra | Concentrate for injection 200 mg in 10 mL | juvenile idiopathic arthritis | Initial treatment - Initial 4 (Temporary listing - change of treatment from another biological medicine to tocilzumab after resolution of the critical shortage of tocilizumab) | null | true | AUTHORITY_REQUIRED | Private | 4,030 | 2,024 | AUGUST |
12795K | tocilizumab | Actemra | Concentrate for injection 200 mg in 10 mL | juvenile idiopathic arthritis | Initial treatment - Initial 4 (Temporary listing - change of treatment from another biological medicine to tocilizumab after resolution of the critical shortage of tocilizumab) | null | true | AUTHORITY_REQUIRED | Private | 4,030 | 2,024 | AUGUST |
13685G | tocilizumab | Actemra Subcutaneous Injection | Injection 162 mg in 0.9 mL single use pre-filled syringe | rheumatoid arthritis | Subsequent continuing treatment | 14499 | true | STREAMLINED | Any | 4,030 | 2,024 | AUGUST |
13763J | adalimumab | Yuflyma | Injection 40 mg in 0.4 mL pre-filled syringe | ankylosing spondylitis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) | null | true | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
13763J | adalimumab | Adalicip | Injection 40 mg in 0.4 mL pre-filled syringe | ankylosing spondylitis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) | null | true | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
13763J | adalimumab | Yuflyma | Injection 40 mg in 0.4 mL pre-filled syringe | ankylosing spondylitis | Initial treatment - Initial 1 (new patient) | null | true | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
13763J | adalimumab | Adalicip | Injection 40 mg in 0.4 mL pre-filled syringe | ankylosing spondylitis | Initial treatment - Initial 1 (new patient) | null | true | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
13763J | adalimumab | Yuflyma | Injection 40 mg in 0.4 mL pre-filled syringe | ankylosing spondylitis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) | null | true | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
13763J | adalimumab | Adalicip | Injection 40 mg in 0.4 mL pre-filled syringe | ankylosing spondylitis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) | null | true | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
12364R | adalimumab | Humira | Injection 40 mg in 0.4 mL pre-filled syringe | juvenile idiopathic arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
12364R | adalimumab | Adalicip | Injection 40 mg in 0.4 mL pre-filled syringe | juvenile idiopathic arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
12364R | adalimumab | Yuflyma | Injection 40 mg in 0.4 mL pre-filled syringe | juvenile idiopathic arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
12364R | adalimumab | Humira | Injection 40 mg in 0.4 mL pre-filled syringe | juvenile idiopathic arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after break in biological medicine of less than 24 months) | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
12364R | adalimumab | Adalicip | Injection 40 mg in 0.4 mL pre-filled syringe | juvenile idiopathic arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after break in biological medicine of less than 24 months) | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
12364R | adalimumab | Yuflyma | Injection 40 mg in 0.4 mL pre-filled syringe | juvenile idiopathic arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after break in biological medicine of less than 24 months) | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
12364R | adalimumab | Humira | Injection 40 mg in 0.4 mL pre-filled syringe | juvenile idiopathic arthritis | Initial treatment - Initial 1 (new patient) | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
12364R | adalimumab | Adalicip | Injection 40 mg in 0.4 mL pre-filled syringe | juvenile idiopathic arthritis | Initial treatment - Initial 1 (new patient) | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
12364R | adalimumab | Yuflyma | Injection 40 mg in 0.4 mL pre-filled syringe | juvenile idiopathic arthritis | Initial treatment - Initial 1 (new patient) | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
12364R | adalimumab | Humira | Injection 40 mg in 0.4 mL pre-filled syringe | juvenile idiopathic arthritis | Initial treatment - Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after break of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
12364R | adalimumab | Adalicip | Injection 40 mg in 0.4 mL pre-filled syringe | juvenile idiopathic arthritis | Initial treatment - Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after break of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
12364R | adalimumab | Yuflyma | Injection 40 mg in 0.4 mL pre-filled syringe | juvenile idiopathic arthritis | Initial treatment - Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after break of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
13332Q | etanercept | Enbrel | Injections 50 mg in 1 mL single use pre-filled syringes, 4 | juvenile idiopathic arthritis | Continuing treatment | 14155 | true | STREAMLINED | Private | 4,030 | 2,024 | AUGUST |
12625L | upadacitinib | Rinvoq | Tablet 15 mg | ankylosing spondylitis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
12625L | upadacitinib | Rinvoq | Tablet 15 mg | ankylosing spondylitis | Initial treatment - Initial 1 (new patient) | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
12625L | upadacitinib | Rinvoq | Tablet 15 mg | ankylosing spondylitis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
12625L | upadacitinib | Rinvoq | Tablet 15 mg | ankylosing spondylitis | Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
9659J | tocilizumab | Actemra | Concentrate for injection 400 mg in 20 mL | rheumatoid arthritis | First continuing treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Public | 4,030 | 2,024 | AUGUST |
9659J | tocilizumab | Actemra | Concentrate for injection 400 mg in 20 mL | rheumatoid arthritis | Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply | null | true | AUTHORITY_REQUIRED | Public | 4,030 | 2,024 | AUGUST |
9659J | tocilizumab | Actemra | Concentrate for injection 400 mg in 20 mL | rheumatoid arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) | null | false | AUTHORITY_REQUIRED | Public | 4,030 | 2,024 | AUGUST |
9659J | tocilizumab | Actemra | Concentrate for injection 400 mg in 20 mL | rheumatoid arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) | null | false | AUTHORITY_REQUIRED | Public | 4,030 | 2,024 | AUGUST |
9659J | tocilizumab | Actemra | Concentrate for injection 400 mg in 20 mL | rheumatoid arthritis | First continuing treatment | null | false | AUTHORITY_REQUIRED | Public | 4,030 | 2,024 | AUGUST |
9659J | tocilizumab | Actemra | Concentrate for injection 400 mg in 20 mL | rheumatoid arthritis | Initial treatment - Initial 1 (new patient) | null | false | AUTHORITY_REQUIRED | Public | 4,030 | 2,024 | AUGUST |
11481G | infliximab | Inflectra | Powder for I.V. infusion 100 mg | rheumatoid arthritis | Subsequent continuing treatment | null | false | AUTHORITY_REQUIRED | Public | 4,030 | 2,024 | AUGUST |
11481G | infliximab | Renflexis | Powder for I.V. infusion 100 mg | rheumatoid arthritis | Subsequent continuing treatment | null | false | AUTHORITY_REQUIRED | Public | 4,030 | 2,024 | AUGUST |
11481G | infliximab | Remicade | Powder for I.V. infusion 100 mg | rheumatoid arthritis | Subsequent continuing treatment | null | false | AUTHORITY_REQUIRED | Public | 4,030 | 2,024 | AUGUST |
1476Q | tocilizumab | Actemra | Concentrate for injection 80 mg in 4 mL | juvenile idiopathic arthritis | Initial treatment - Initial 1 (new patient) | null | true | AUTHORITY_REQUIRED | Public | 4,030 | 2,024 | AUGUST |
1476Q | tocilizumab | Actemra | Concentrate for injection 80 mg in 4 mL | juvenile idiopathic arthritis | Balance of supply for Initial treatment - Initial 1 (new patient) or Initial 2 (retrial or recommencement of treatment after a break of less than 12 months) or Initial 3 (recommencement of treatment after a break of more than 12 months) | null | true | AUTHORITY_REQUIRED | Public | 4,030 | 2,024 | AUGUST |
1476Q | tocilizumab | Actemra | Concentrate for injection 80 mg in 4 mL | juvenile idiopathic arthritis | Initial treatment - Initial 2 (retrial or recommencement of treatment after a break of less than 12 months) | null | true | AUTHORITY_REQUIRED | Public | 4,030 | 2,024 | AUGUST |
1476Q | tocilizumab | Actemra | Concentrate for injection 80 mg in 4 mL | juvenile idiopathic arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break of more than 12 months) | null | true | AUTHORITY_REQUIRED | Public | 4,030 | 2,024 | AUGUST |
10895K | secukinumab | Cosentyx | Injection 150 mg in 1 mL pre-filled pen | psoriatic arthritis | Continuing treatment | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
10895K | secukinumab | Cosentyx | Injection 150 mg in 1 mL pre-filled pen | psoriatic arthritis | Continuing treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
6496X | infliximab | Inflectra | Powder for I.V. infusion 100 mg | psoriatic arthritis | First continuing treatment | null | false | AUTHORITY_REQUIRED | Private | 4,030 | 2,024 | AUGUST |
6496X | infliximab | Remicade | Powder for I.V. infusion 100 mg | psoriatic arthritis | First continuing treatment | null | false | AUTHORITY_REQUIRED | Private | 4,030 | 2,024 | AUGUST |
6496X | infliximab | Renflexis | Powder for I.V. infusion 100 mg | psoriatic arthritis | First continuing treatment | null | false | AUTHORITY_REQUIRED | Private | 4,030 | 2,024 | AUGUST |
6496X | infliximab | Inflectra | Powder for I.V. infusion 100 mg | psoriatic arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) | null | false | AUTHORITY_REQUIRED | Private | 4,030 | 2,024 | AUGUST |
6496X | infliximab | Remicade | Powder for I.V. infusion 100 mg | psoriatic arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) | null | false | AUTHORITY_REQUIRED | Private | 4,030 | 2,024 | AUGUST |
6496X | infliximab | Renflexis | Powder for I.V. infusion 100 mg | psoriatic arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) | null | false | AUTHORITY_REQUIRED | Private | 4,030 | 2,024 | AUGUST |
6496X | infliximab | Inflectra | Powder for I.V. infusion 100 mg | psoriatic arthritis | Initial treatment - Initial 1 (new patient) | null | false | AUTHORITY_REQUIRED | Private | 4,030 | 2,024 | AUGUST |
6496X | infliximab | Remicade | Powder for I.V. infusion 100 mg | psoriatic arthritis | Initial treatment - Initial 1 (new patient) | null | false | AUTHORITY_REQUIRED | Private | 4,030 | 2,024 | AUGUST |
6496X | infliximab | Renflexis | Powder for I.V. infusion 100 mg | psoriatic arthritis | Initial treatment - Initial 1 (new patient) | null | false | AUTHORITY_REQUIRED | Private | 4,030 | 2,024 | AUGUST |
6496X | infliximab | Inflectra | Powder for I.V. infusion 100 mg | psoriatic arthritis | Continuing treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Private | 4,030 | 2,024 | AUGUST |
6496X | infliximab | Remicade | Powder for I.V. infusion 100 mg | psoriatic arthritis | Continuing treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Private | 4,030 | 2,024 | AUGUST |
6496X | infliximab | Renflexis | Powder for I.V. infusion 100 mg | psoriatic arthritis | Continuing treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Private | 4,030 | 2,024 | AUGUST |
6496X | infliximab | Inflectra | Powder for I.V. infusion 100 mg | psoriatic arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) | null | false | AUTHORITY_REQUIRED | Private | 4,030 | 2,024 | AUGUST |
6496X | infliximab | Remicade | Powder for I.V. infusion 100 mg | psoriatic arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) | null | false | AUTHORITY_REQUIRED | Private | 4,030 | 2,024 | AUGUST |
6496X | infliximab | Renflexis | Powder for I.V. infusion 100 mg | psoriatic arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) | null | false | AUTHORITY_REQUIRED | Private | 4,030 | 2,024 | AUGUST |
6496X | infliximab | Inflectra | Powder for I.V. infusion 100 mg | psoriatic arthritis | Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply | null | true | AUTHORITY_REQUIRED | Private | 4,030 | 2,024 | AUGUST |
6496X | infliximab | Remicade | Powder for I.V. infusion 100 mg | psoriatic arthritis | Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply | null | true | AUTHORITY_REQUIRED | Private | 4,030 | 2,024 | AUGUST |
6496X | infliximab | Renflexis | Powder for I.V. infusion 100 mg | psoriatic arthritis | Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply | null | true | AUTHORITY_REQUIRED | Private | 4,030 | 2,024 | AUGUST |
11320T | certolizumab pegol | Cimzia | Solution for injection 200 mg in 1 mL pre-filled pen | ankylosing spondylitis | Continuing treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
11320T | certolizumab pegol | Cimzia | Solution for injection 200 mg in 1 mL pre-filled pen | ankylosing spondylitis | Continuing treatment | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
11721X | tocilizumab | Actemra Subcutaneous Injection | Injection 162 mg in 0.9 mL single use pre-filled syringe | giant cell arteritis | Continuing treatment | null | true | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
9615C | etanercept | Enbrel | Injections 50 mg in 1 mL single use pre-filled syringes, 4 | juvenile idiopathic arthritis | Initial treatment - Initial 1 (new patient) | null | true | AUTHORITY_REQUIRED | Private | 4,030 | 2,024 | AUGUST |
9615C | etanercept | Enbrel | Injections 50 mg in 1 mL single use pre-filled syringes, 4 | juvenile idiopathic arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) | null | true | AUTHORITY_REQUIRED | Private | 4,030 | 2,024 | AUGUST |
9615C | etanercept | Enbrel | Injections 50 mg in 1 mL single use pre-filled syringes, 4 | juvenile idiopathic arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) | null | true | AUTHORITY_REQUIRED | Private | 4,030 | 2,024 | AUGUST |
9615C | etanercept | Enbrel | Injections 50 mg in 1 mL single use pre-filled syringes, 4 | juvenile idiopathic arthritis | Initial treatment - Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply | null | true | AUTHORITY_REQUIRED | Private | 4,030 | 2,024 | AUGUST |
9077R | adalimumab | Amgevita | Injection 40 mg in 0.8 mL pre-filled syringe | ankylosing spondylitis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
Subsets and Splits
No saved queries yet
Save your SQL queries to embed, download, and access them later. Queries will appear here once saved.